An established cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM), mavacamten (Camzyos) showed potential for ...

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

USA: A recent study from the EMBARK-HFpEF trial has revealed promising results regarding using mavacamten, a cardiac myosin ...

Introduction: Heart failure with preserved ejection fraction (HFpEF) is a heterogenous clinical syndrome that accounts for nearly half of all heart failure cases world-wide. The pathophysiological ...

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...

For patients with HFPEF and other underlying comorbidities ... as defined by prespecified clinical and echocardiographic criteria, and hospitalized for a cardiovascular cause within the previous ...

Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.

Background: Transition from fatty acid oxidation to glycolysis is linked to oncometabolism and cardiac hypertrophy. We hypothesize that such a metabolic shift is pivotal in driving HFpEF in 3 murine ...

Among the benefits of semaglutide, the GLP-1 receptor agonist may protect against heart failure events in patients with type 2 diabetes and CKD.

But the diagnosis of HFpEF should be cautious. Heart failure (HF), which affects approximately ... The meta-analysis comprised eligible studies meeting the following criteria: (1) exploration of the ...